Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study
Authors:
- Marion LamMLMarion Lam
- Valérie TouitouVTValérie Touitou
- Sylvain ChoquetSCSylvain Choquet
- Nathalie CassouxNCNathalie Cassoux
- Hervé GhesquièresHGHervé Ghesquières
- Laurent KodjikianLaurent Kodjikian
- Anna SchmittASAnna Schmitt
- Sarra GattoussiSGSarra Gattoussi
- Émeline TabouretÉmeline Tabouret
- Magali SampoMSMagali Sampo
- Karine Angioi‐DuprezKAKarine Angioi‐Duprez
Open Access
- 17 April 2021
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 96 (7) , 823-833
Abstract
The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high‐dose methotrexate (IV HD‐MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first‐line treatment with HD‐MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL‐10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL‐10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow‐up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression‐free survival, ocular‐free survival and brain‐free survival were 75, 18, 29 and 73 months, respectively. IV HD‐MTX based systemic therapy as a first‐line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL‐10.Keywords
This publication has 38 references indexed in Scilit:
- Effect of Intravitreal Methotrexate and Rituximab on Interleukin-10 Levels in Aqueous Humor of Treated Eyes with Vitreoretinal LymphomaPLOS ONE, 2013
- Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group SymposiumThe Oncologist, 2011
- Interleukin-10 and Interleukin-6 in Aqueous Humor during Treatment of Vitreoretinal Lymphoma with Intravitreally Injected MethotrexateOphthalmic Research, 2009
- Primary CNS lymphoma with intraocular involvementNeurology, 2008
- Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experienceBritish Journal of Ophthalmology, 2008
- Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group ReportAnnals of Oncology, 2007
- IL-10 Measurement in Aqueous Humor for Screening Patients with Suspicion of Primary Intraocular LymphomaInvestigative Ophthalmology & Visual Science, 2007
- Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapyEye, 2006
- Biological diagnosis of primary intraocular lymphomaBritish Journal of Haematology, 2004
- Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvementHistorical imageOphthalmology, 2002